Hemostemix Inc (CVE:HEM)’s share price rose 15% on Thursday . The company traded as high as C$0.12 and last traded at C$0.12. Approximately 847,550 shares were traded during trading, an increase of 211% from the average daily volume of 272,336 shares. The stock had previously closed at C$0.10.

ILLEGAL ACTIVITY NOTICE: “Hemostemix (HEM) Stock Price Up 15%” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/11/10/hemostemix-hem-stock-price-up-15.html.

About Hemostemix (CVE:HEM)

Hemostemix Inc, a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia.

Recommended Story: The Discount Rate – What You Need to Know

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.